Engflag

Lofepramine

Quick links to important sections

Lofepramine

Lofepramine_EN

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Lofepramine

Property Description
Active ingredient Lofepramine Hydrochloride
Form Oral tablet (film-coated)
Pharmacological class Tricyclic Antidepressant (TCA)
Common use Management of depressive illness
Origin Synthetic (Dibenzoazepine derivative)

Defining Lofepramine: Drug Type and Classification

Lofepramine, typically administered as the salt Lofepramine Hydrochloride, is a prescription-only psychotropic agent that belongs to the Tricyclic Antidepressant (TCA) class of medications. Its chemical foundation is a dibenzazepine derivative, which places it within this historic group of compounds used to manage mood disorders. Lofepramine holds a distinct position, often recognized as a third-generation TCA, setting it apart from older substances like imipramine. This differentiation is clinically recognized for its comparatively lower affinity for specific peripheral receptors, such as the Muscarinic Acetylcholine Receptors. This more selective action on central nervous system pathways is a key characteristic of the substance.

General Purpose and Unique Action

The general purpose of Lofepramine is to help stabilize mood and manage conditions like depressive illness and Major Depressive Disorder (MDD), representing a typical therapeutic use scenario for its class. Its core physiological action is that of a non-selective monoamine reuptake inhibitor (NSRI). This means it works by modulating the concentrations of chemical messengers—specifically, increasing the availability of norepinephrine and, to a lesser extent, serotonin—in the brain's synaptic spaces. Furthermore, a unique characteristic of Lofepramine is its status as a prodrug that metabolizes into the highly effective active compound desipramine. This two-part action, involving both the parent drug and the potent metabolite, ensures a sustained and focused intervention on the targeted neurotransmitter systems.

What side effects are possible with Lofepramine?

Possible side effects and safety information

The safety profile of Lofepramine is formally defined by regulatory documents, which categorize potential adverse reactions by the frequency of their occurrence and the body systems they affect. This information establishes the officially recognized risk profile of the medication, primarily associated with its classification as a Tricyclic Antidepressant (TCA).

Official Adverse Reaction Frequencies

Adverse reactions are classified according to regulatory frequency standards:

  • Common (may affect up to 1 in 10 people): Includes effects such as dry mouth, constipation, dizziness, headache, tremor, sweating, blurred vision, tachycardia (rapid heart rate), and orthostatic hypotension (low blood pressure upon standing).
  • Rare (may affect up to 1 in 1,000 people): Includes serious reactions such as jaundice, disturbances in heart rhythm (arrhythmias), and the severe blood disorder agranulocytosis.
  • Not Known (frequency cannot be estimated): This category includes safety notes on suicidal ideation and suicidal behaviour, which is a known safety consideration for antidepressant treatments.

Contextual Safety Notes

Certain safety considerations are tied to the patient group or the phase of treatment. The label documents that effects like anticholinergic symptoms and sedation may be more pronounced at the start of treatment and are expected to diminish. Furthermore, older adults may show increased sensitivity to certain effects, particularly orthostatic hypotension and anticholinergic symptoms.

Lofepramine use is subject to specific regulatory limitations, including a contraindication for individuals with severe hepatic impairment. There is also a mandatory safety restriction prohibiting concurrent use with Monoamine Oxidase Inhibitors (MAOIs), as documented in the official prescribing information.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory documents indicate that an overdose of lofepramine requires immediate medical attention, even if symptoms appear mild or have not yet developed. This drug belongs to a class (tricyclic antidepressants) commonly associated with serious overdose complications, including life-threatening cardiac arrhythmias, seizures, and coma.

Lofepramine is specifically noted in regulatory safety data to have a significantly lower risk of death in overdose compared to other drugs in its class. However, a severe or fatal outcome remains possible, particularly if the overdose involves other substances (such as alcohol, hypnotics, or other psychotropic drugs).

Overdose Manifestations

Symptoms that indicate a potential overdose and require contacting a doctor immediately include signs of toxicity affecting the central nervous system and the autonomic nervous system:

  • Neurological: Agitation, hallucinations, coma, tremor, and exaggeration of reflexes.
  • Autonomic/Systemic: Excessive sweating, increased muscle tension, and a high body temperature (hyperpyrexia, with temperature above 38 C).

The management of a lofepramine overdose primarily involves attempts to reduce the body’s absorption of the drug and continuous monitoring for adverse effects, especially on the heart. It is crucial to seek emergency help right away if an overdose is suspected.

Therapeutic Uses of Lofepramine

What Lofepramine Treats: Main Uses and Benefits

Lofepramine is commonly used in situations involving certain distressing symptoms linked to depressive illness, including Major Depressive Disorder (MDD). It is applied across domains where additional symptomatic support is needed. The medication is considered relevant for managing symptoms associated with depressive illness.

It is considered relevant in contexts marked by acute or episodic symptom changes to ease the central symptoms of persistent low mood, despair, and emotional distress. Lofepramine generally assists with managing symptom clusters that can become intense or disruptive, such as sleep disturbances and loss of energy, which interfere with daily comfort. This application is useful for conditions presenting with acute episodes and may be part of symptomatic management for complex presentations, including addressing certain forms of neurological discomfort often linked to this therapeutic class. The medication assists with maintaining functional stability when symptoms are more noticeable.

“Lofepramine contributes to easing the overall symptom load, supporting patients during difficult episodes.”

Quick Fact: Relief for Core Depressive Symptoms

Lofepramine is generally used for managing symptoms related to pervasive mood distress and associated functional deficits in adults and older adults, which supports general well-being during symptomatic phases.

Regulatory References

  1. UK Summary of Product Characteristics

Eligibility and Restrictions for Use

Lofepramine is an antidepressant that is only appropriate for use in adults who do not have specific contraindicating health issues, as defined by regulatory labeling. The rules for who can and cannot use this medicine are divided into strict exclusions and conditional limitations.

Contraindicated Populations (Must Not Use)

The medicine is formally contraindicated for patients with:

  • Hypersensitivity to lofepramine or other tricyclic antidepressants.
  • Severe liver or renal impairment.
  • Acute mania or acute poisoning (e.g., alcoholic, hypnotic, analgesic).
  • Cardiac issues, including heart block, cardiac arrhythmias, or the recovery phase following a myocardial infarction.
  • Untreated narrow-angle glaucoma or conditions causing a risk of paralytic ileus.
  • Concurrent use with, or within two weeks of stopping, a Monoamine Oxidase Inhibitor (MAOI).

Restricted and Special-Population Use

  • Age: Use is not recommended for children and adolescents under 18 years, as safety and efficacy are not established. The elderly may require lower doses and need close monitoring due to an increased risk of specific adverse effects.
  • Pregnancy/Lactation: Use is not recommended during pregnancy or breastfeeding, as the medicine passes into breast milk and may affect the infant.
  • Caution Required: Patients with a history of epilepsy, mania, cardiovascular disease, or hyperthyroidism should use Lofepramine only with particular caution and monitoring.

What should I know about interactions with other medicines?

Lofepramine Interactions with other medicines and products

This section outlines the officially documented interaction patterns for Lofepramine, as found in governmental regulatory prescribing information. This information details specific prohibited combinations and substances that may alter the drug's concentration or synergistic effects.

Documented High-Risk Combinations

Co-administration with Monoamine Oxidase Inhibitors (MAOIs) is explicitly prohibited. A mandatory two-week separation window is required after discontinuing MAOI therapy before starting Lofepramine. The use of Amiodarone and Terfenadine must also be avoided due to the documented increase in the risk of severe ventricular arrhythmias.

Exposure and Concentration Changes

Certain medicinal products are officially stated to modify Lofepramine's plasma concentrations. Inhibitors such as Cimetidine, specific Selective Serotonin Reuptake Inhibitors (SSRIs) (e.g., Fluoxetine), Neuroleptic Agents, and Quinidine may lead to increased drug exposure. Conversely, Rifampicin is documented to accelerate metabolism, which results in decreased plasma concentrations.

Pharmacodynamic Effects and Cautions

Lofepramine has documented additive risk interactions, including the potential for Serotonin Syndrome when combined with agents like Buprenorphine. It may also decrease or abolish the blood pressure-lowering effects of certain Adrenergic Neurone Blockers (e.g., Clonidine). Caution is advised for elderly patients, who are noted as being more susceptible to certain adverse reactions related to these interaction effects.

Mechanism of Action

How Lofepramine Works

Targeting Monoamine Transporters

Lofepramine acts as a prodrug, with its primary pharmacologic effect mediated by its active metabolite, desipramine. This metabolite inhibits the reuptake of the monoamine neurotransmitters, primarily norepinephrine (NE) and, to a lesser extent, serotonin (5-HT), by binding to their respective transporters on presynaptic nerve terminals.

This blockade increases the concentration of NE and 5-HT in the synaptic cleft, initiating an alteration in synaptic signaling within the central nervous system.

Downstream Physiological Adjustments

The sustained increase in neurotransmitter availability leads to secondary, slower adjustments in the sensitivity and activity of postsynaptic receptors over a period of weeks. This process of neural adaptation is associated with the long-term modulation of neural circuit activity and contributes to long-term functional adjustments within the central nervous system.

In addition to its primary effect, the drug engages secondary receptor systems, including histamine left( H1 ight) and acetylcholine (muscarinic) receptors. These interactions contribute to the drug's full physiological consequence profile, influencing various systemic responses and downstream physiological effects.

Dosage and Administration Information

How to Use Lofepramine

Lofepramine is administered strictly via the oral route, available as a film-coated tablet (70 mg strength) and an oral suspension (70 mg/5 ml). The total daily dose must always be taken in divided doses and can be taken with or without food.

Standard Dosage and Administration Protocol

The typical total daily regimen for adults is 140 mg to 210 mg, determined by individual response. This total must be partitioned, often resulting in a twice-daily or three-times-daily schedule, with the maximum single dose not exceeding 70 mg. A lower initial dose of 70 mg once daily may be utilized during the first week for specific patient presentations.

Handling and Population-Specific Rules

If the oral suspension is used, the bottle must be shaken well before each administration. The score line on the film-coated tablet is solely intended to facilitate swallowing and is not meant to divide the tablet into equal doses for numerical reduction.

Usage recommendations are adjusted for certain populations: Older adults may respond adequately to lower dosages. The use of Lofepramine is not recommended for patients under 18 years of age due to unestablished safety and efficacy. If a dose is missed, the standard procedure is to skip the missed dose and resume the next scheduled dose as normal, without attempting to take a double dose. Discontinuation of treatment requires a process of gradual dose reduction rather than abrupt cessation.

Recent Clinical Evidence

Research evidence / Overview of studies for Lofepramine

Evidence for use in Major Depressive Disorder (MDD)

Lofepramine was evaluated in a number of short-term randomized controlled trials (RCTs) and systematic reviews involving adults with Major Depressive Disorder, including those for whom prior antidepressant treatments were unsuccessful. These studies generally researched how changes in validated depression rating scales and the percentages of participants meeting predefined criteria for response (a notable reduction in symptoms) or remission were observed, compared to other treatments or placebo.

The findings describe patterns observed in the studies where participants experienced measurements of reductions in the total scores on the depression scales during the defined study periods, typically lasting 4 to 12 weeks. Some trials data show patterns related to a higher percentage of participants meeting the criteria for response or remission compared to control groups in those short-term settings.

Evidence for use in Generalized Anxiety Disorder (GAD)

Lofepramine was studied in adults with Generalized Anxiety Disorder (GAD), which are conditions characterized by fluctuating or episodic manifestations of worry and anxiety. The studies monitored outcomes using anxiety rating scales and outcomes reflecting daily functioning or activity level over typically short durations, often around 4 to 10 weeks.

What is Still Uncertain About Lofepramine

Research provides context but not individual predictions about the experience of using Lofepramine. Long-term effects are not fully established for any of the studied conditions, and follow-up durations were limited across many of the core trials. Evidence is limited for specific groups outside of the primary adult populations. Data for certain groups remain insufficient, including children, adolescents, or older adults (geriatric patients), meaning the results reflect only the specific populations included in the core trials.

Frequently Asked Questions (FAQ)

Common questions about Lofepramine (FAQ)

Q: What is Lofepramine and how does it work?

A: Lofepramine is a tricyclic antidepressant (TCA) that is primarily used to treat depressive illness. It works in the brain by affecting the levels of certain natural substances, primarily by acting as a more potent inhibitor of the norepinephrine reuptake pump than the serotonin reuptake pump. This action helps to regulate mood.

Q: How long does it usually take for Lofepramine to start working for depression?

A: While some initial effects, such as a reduction in insomnia or anxiety, might be noticed sooner, the full therapeutic actions for depression are often delayed, typically taking about 2 to 4 weeks to become apparent. If no improvement is seen after 6 to 8 weeks, a healthcare provider may need to reassess the treatment.

Q: What are some common side effects of Lofepramine?

A: Like all medications, Lofepramine can cause side effects. Common ones include:

  • Anticholinergic effects: Dry mouth, constipation, blurred vision, and difficulty emptying the bladder.
  • Neurological effects: Sedation, fatigue, dizziness, headache, anxiety, and restlessness.
  • Gastrointestinal effects: Nausea, diarrhea, heartburn, and unusual taste in the mouth.
  • Other common effects: Increased appetite, weight gain, sweating, and sexual dysfunction.

Q: What are the risks of suddenly stopping Lofepramine treatment?

A: Suddenly stopping Lofepramine can lead to withdrawal symptoms, which may include:

  • Unsteadiness, vertigo, or dizziness.
  • Altered sensations, such as electric shock feelings.
  • Changes in mood, like irritability, anxiety, or low mood.
  • Restlessness or agitation.
  • Problems with sleep.
  • Sweating.
  • Gastrointestinal symptoms, such as nausea.
  • Palpitations.

Withdrawal symptoms do not typically happen immediately upon stopping the medication. If these symptoms occur, a healthcare provider may advise returning to the previous dose and reducing the medication more slowly.

Q: Is Lofepramine considered a safe TCA in overdose compared to other similar drugs?

A: Historically, Lofepramine has been associated with a lower risk of death in overdose compared to many other tricyclic antidepressants. However, it is still a potent medication, and all TCAs, including Lofepramine, are associated with a risk of cardiovascular adverse events, particularly in overdose.

Q: Are there any specific monitoring tests needed when taking Lofepramine, especially for older adults?

A: Yes. For patients over the age of 50, a baseline electrocardiogram (ECG) is typically recommended to check heart function before starting treatment. Additionally, monitoring of weight and BMI is recommended during treatment, and for patients at risk for electrolyte imbalances (e.g., those on diuretics), baseline and periodic measurements of serum potassium and magnesium may be performed.

Q: What are some serious side effects or warnings associated with Lofepramine?

A: Although less common, Lofepramine can be associated with serious side effects. These may include:

  • Cardiac issues: Arrhythmias, QTc prolongation, orthostatic hypotension (low blood pressure on standing), and sudden death.
  • Neurological issues: Seizures (due to a lowered seizure threshold), and rare induction of mania.
  • Gastrointestinal issues: Paralytic ileus (a rare but serious bowel obstruction).
  • Liver issues: Hepatic failure.
  • Suicidal ideation: Activation of suicidal ideation and behavior, particularly in the short-term and in younger adults (below age 25) starting antidepressant therapy.

How should Lofepramine be stored and disposed of?

How to Store and Dispose of Lofepramine?

The storage and disposal of Lofepramine must strictly follow the requirements defined in official regulatory labeling.

Official Storage Requirements

Formulation Temperature Requirement Packaging Rule
Tablets Do not store above 25 C. Store in the original package.
Oral Suspension Store between 4 C and 25 C; protect from direct light. Keep the bottle tightly closed.

All presentations of the medicine must be kept out of the sight and reach of children. The product must not be used after the printed expiry date.

Disposal

To protect the environment, the official guidance requires that unused or expired Lofepramine must not be thrown away via household waste or wastewater. Patients are directed to return the medicine to a pharmacist or a local pharmaceutical waste collection point for proper disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Lofepramine found in:

A-Z Index: